Plain-English translation of NCT06716814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a continuation study for people with moderate or severe hemophilia A (a bleeding disorder) who completed an earlier trial of . If you finished one of the original studies and benefited from the treatment, this trial lets you keep receiving the same medication while researchers continue to monitor your safety and how well it works. The study will continue until the medication becomes available through regular prescription in your country, or until March 2027.
People with hemophilia A who were improving on this new treatment deserve to continue it rather than having to stop when their original trial ended. This trial bridges that gap and lets doctors keep watching to make sure the treatment stays safe and effective over a longer period of time.
You likely qualify if…
You likely don't qualify if…
You will continue to receive a weekly injection of the medication at home, just as you were doing in the earlier study. You'll visit the clinic at the start of the study, then approximately every 13 weeks for check-ups or brief phone calls. You'll keep a simple diary to track how you're doing. The study lasts until the medication becomes commercially available in your country or until early 2027, whichever comes first, with a final safety check about two weeks after your last visit.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Bulgaria
France